Amica Mutual Insurance Co. Takes Position in The Cooper Companies, Inc. $COO

Amica Mutual Insurance Co. acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 14,893 shares of the medical device company’s stock, valued at approximately $1,060,000.

A number of other large investors have also recently added to or reduced their stakes in COO. Campbell & CO Investment Adviser LLC raised its position in Cooper Companies by 29.8% during the second quarter. Campbell & CO Investment Adviser LLC now owns 12,487 shares of the medical device company’s stock worth $889,000 after acquiring an additional 2,866 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Cooper Companies by 11.1% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 383,736 shares of the medical device company’s stock worth $27,307,000 after purchasing an additional 38,427 shares in the last quarter. Aviva PLC raised its position in shares of Cooper Companies by 6.9% during the 2nd quarter. Aviva PLC now owns 148,728 shares of the medical device company’s stock worth $10,583,000 after purchasing an additional 9,576 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Cooper Companies during the 2nd quarter worth approximately $514,000. Finally, Wedbush Securities Inc. lifted its stake in Cooper Companies by 13.5% in the 2nd quarter. Wedbush Securities Inc. now owns 13,860 shares of the medical device company’s stock valued at $986,000 after buying an additional 1,648 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on COO shares. Barclays initiated coverage on Cooper Companies in a research report on Monday, October 13th. They set an “overweight” rating and a $85.00 price target for the company. Mizuho dropped their price objective on Cooper Companies from $105.00 to $90.00 and set an “outperform” rating for the company in a research report on Wednesday, July 16th. The Goldman Sachs Group set a $64.00 target price on shares of Cooper Companies and gave the company a “sell” rating in a report on Wednesday, October 1st. Weiss Ratings downgraded shares of Cooper Companies from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday. Finally, Morgan Stanley set a $76.00 price objective on shares of Cooper Companies and gave the company an “equal weight” rating in a research report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.77.

Insiders Place Their Bets

In other news, EVP Brian G. Andrews purchased 1,525 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was bought at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the purchase, the executive vice president directly owned 22,191 shares of the company’s stock, valued at $1,457,504.88. The trade was a 7.38% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Daniel G. Mcbride acquired 3,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was purchased at an average price of $65.04 per share, for a total transaction of $195,120.00. Following the completion of the acquisition, the chief operating officer owned 63,120 shares in the company, valued at approximately $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders bought 17,975 shares of company stock worth $1,216,346. Corporate insiders own 1.98% of the company’s stock.

Cooper Companies Price Performance

COO opened at $70.10 on Friday. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $106.63. The company’s 50 day simple moving average is $69.24 and its 200 day simple moving average is $72.64. The stock has a market capitalization of $13.94 billion, a PE ratio of 34.53, a P/E/G ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.07 by $0.03. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. Cooper Companies’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a share buyback program on Wednesday, September 17th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical device company to buy up to 15.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.